Gilead Sciences Inc. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Cellarity Inc. has divulged DCN1-like protein 1 (DCUN1D1; RP42) and/or DCN2 inhibitors reported to be useful for treatment of sickle cell and thalassemia disorder.

Korea Institute of Science and Technology has identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.

Shanghai Yingli Pharmaceutical Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Bristol Myers Squibb Co. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Pillai Universal LLC has prepared and tested compounds acting as protein kinase inhibitors reported to be useful for the treatment of cancer.

Halda Therapeutics LLC has synthesized heterobifunctional compounds able to bind both androgen receptor and bromodomain-containing protein 4 (BRD4; HUNK1) reported to be useful for the treatment of cancer.

ADC Therapeutics SA has described antibody-drug conjugates comprising antibody targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) covalently linked to exatecan through a linker reported to be useful for the treatment of ovarian cancer and non-small-cell lung cancer (NSCLC).

Gen1e Lifesciences Inc. has disclosed drugs targeting extracellular-regulated kinase (ERK) reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune and lung diseases.

Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has discovered compounds acting as diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.